Fig. 8: Determination of the off-rate and KD of mutant 4.
From: The RESP AI model accelerates the identification of tight-binding antibodies
Experimental validation of the Koff and KD on the yeast surface. A WT vs. Mutant 4 scFv dissociation after 92 h at RT on the yeast surface, T1/2 is half-life. B Comparison of WT Atezolizumab, Mutant 4, Durvalumab, and Avelumab scFv dissociation over 28 h at RT on the yeast surface. C Binding affinity (KD) measurements determined on the yeast surface between scFv and PD-L1 (3 independent measurements, also see Supplementary Fig. 7)). Source data are provided as a source data file for this figure.
